Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Latest filing published 18 Sept 2024 for G1 Therapeutics, Inc..
Filing timeline
BuySaleMark Avagliano
Insider track record
Disclosed buys
0
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Mark Avagliano: trading record in brief
Mark Avagliano (senior executive) discloses dealings in G1 Therapeutics, Inc. to SEC (Form 4). In total, 16 filings cover trades dated from 4 January 2021 to 18 September 2024.
Sales make up the whole of the open-market record (6 sales, €67k). The rest of the record consists of 8 share grants. In 2024 alone, the filings show no purchases and 5 sales.
The latest filing, published on 18 September 2024, reports a transaction in G1 Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Mark Avagliano
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
20,600 sharesCommon StockSEC:0000950170-24-107795:0
2,638 shares@ US$2.507714.5% of flowCommon StockSEC:0001562180-24-005657:0
35,000 shares0Common StockSEC:0001562180-24-005605:0
8,151 shares@ US$4.788885.5% of flowCommon StockSEC:0001562180-24-004057:0
100,000 shares0Common StockSEC:0001562180-24-002949:0
44,760 shares0Common StockSEC:0001562180-24-000323:0
35,000 shares0Common StockSEC:0001562180-23-004098:0
20,600 shares0Common StockSEC:0001562180-23-000251:0
12,000 shares0Common StockSEC:0001562180-22-000303:0
9 of 9 declarations
